A Multicenter, Randomized, Phase IIa/IIb Clinical Trial of 3D1002 Combined With Oxycodone Hydrochloride Sustained-release Tablets in the Treatment of Patients With Moderate to Severe Cancer Pain

This study aims to evaluate the safety and efficacy of 3D1002 alone or in combination with oxycodone hydrochloride sustained-release tablets (OxyContin) for the management of moderate or severe cancer pain.

开始日期2024-09-01

申办/合作机构

思路迪科技（上海）有限公司

NCT06444997 / Not yet recruiting临床4期IIT

Efficacy and Safety of Oxycodone Hydrochloride and Remifentanil for Long-term Analgesia During Invasive Mechanical Ventilation in Postoperative Patients: A Pilot Study

The goal of this clinical trial is to learn if oxycodone hydrochloride works to manage pain in patients requiring mechanical ventilation. It will also assess the safety of oxycodone hydrochloride. The main questions it aims to answer are:
1. Does oxycodone hydrochloride effectively lower the CPOT (Critical Care Pain Observation Tool) score in mechanically ventilated patients?
2. What medical problems do participants have when using oxycodone hydrochloride? Researchers will compare oxycodone hydrochloride to remifentanil to see if oxycodone works better to manage pain in these patients.
Participants will:
Receive either oxycodone hydrochloride injection at a dose of 0.03-0.2 mg/kg/h or remifentanil injection at a dose of 2-9 μg/kg/h.
Have their pain scores assessed every 15 minutes until the CPOT score is less than 3. After reaching the target pain score, assessments will be done every 4 hours.
Have their vital signs and monitoring data recorded.
Have analgesia and sedation scores recorded from days 1 to 7 after administration, with drug dosages adjusted based on pain scores.
Have the incidence of adverse reactions and changes in gastrointestinal function observed and recorded from days 1 to 7 after administration.
If extubated within 7 days, relevant data will be collected based on the time of extubation.
Be followed up on day 28 through the electronic medical record system to gather data on the extubation success rate and incidence of complications within the 28-day period.

开始日期2024-06-01

申办/合作机构

复旦大学附属中山医院

ChiCTR2400080454 / Suspended临床4期IIT

Effect of oxycodone hydrochloride injection in patients diagnosed with sepsis induced acute lung injury

开始日期2024-04-01

申办/合作机构

天津市南开医院

100 项与盐酸羟考酮相关的临床结果

登录后查看更多信息

100 项与盐酸羟考酮相关的转化医学

登录后查看更多信息

100 项与盐酸羟考酮相关的专利（医药）

登录后查看更多信息

470

项与盐酸羟考酮相关的文献（医药）

2023-11-02·Education for primary care : an official publication of the Association of Course Organisers, National Association of GP Tutors, World Organisation of Family Doctors

‘Dopesick’; why a critical view of the literature may save your patient’s life

Article

作者: O'Connor, Raymond

INTRODUCTION:

Teaching critical literature appraisal is challenging. Providing a compelling clinical context using 'cinemeduation' stimulates interest in the topic.

METHODS:

After watching the first episode of the mini-series 'Dopesick', where the scope, timeline and extent of the problem of opioid abuse are clearly seen, abstracts of the period literature strongly supporting the use of Oxycontin for use in chronic pain are shown. All were published in highly ranked medical journals. A simple paper evaluation structure is suggested. It is PPICOREAD which stands for the following questions: Who Paid for the study? What was the Population studied? What was the Intervention given in the study? What was the Control group used? What was the Outcome and was it of clinical significance to you? Was the trial Registered? Was there an Educational element for you? Was there anything Applicable to your practice? What was the Duration of the trial? Is this duration sufficient to reassure you that the trial is relevant to your practice?

RESULTS:

The very poor quality and dishonest nature of the conclusions of these papers are quickly and easily uncovered in a supervised workshop. The causes for these clear discrepancies are discussed. The devastating consequences are described.

2023-10-01·Palliative & supportive care

Naldemedine-induced opioid withdrawal with restlessness as the predominant symptom in a palliative care setting

Article

作者: Sato, Ryota ; Uchida, Nozomu ; Onishi, Hideki ; Ishida, Mayumi ; Yamaguchi, Takefumi ; Sakimoto, Takehiko ; Takahashi, Takao ; Ooya, Yoshitaka

Abstract:

Objectives:

Opioid analgesics play a central role in cancer pain treatment; however, it has been reported that opioid-induced constipation (OIC) develops in 80% of patients using opioid analgesics and leads to a decrease in quality of life. Naldemedine improves constipation without affecting the analgesic action of opioid analgesics via peripheral μ-opioid receptors.

Methods:

We report a terminally ill cancer patient who was diagnosed with opioid withdrawal syndrome (OWS) based on symptoms centered around restlessness and sweating that developed 43 days after administration of naldemedine for OIC.

Results:

The patient was a 78-year-old woman who was diagnosed with stage IVB uterine sarcoma in October, 1 year prior to her visit to our clinic, and underwent chemotherapy after surgery, but the disease became progressive. Thereafter, metastasis to the fourth thoracic vertebrae (Th4) was identified, and loxoprofen and acetaminophen were started for pain at the metastatic site. Oxycodone hydrochloride hydrate 10 mg/day was additionally administered on postoperative day 11, followed by naldemedine 0.2 mg/day for OIC. On the 43rd day after administration, the patient began to wander the hospital ward in a wheelchair and became noticeably restless. OWS due to naldemedine administration was suspected, and naldemedine was discontinued. The symptoms improved 7 days later, and no similar symptoms were observed thereafter.

Significance of results:

Patients receiving palliative care often exhibit psychiatric symptoms such as anxiety and depression, but OWS due to naldemedine should also be considered as a potential cause.

2023-07-28·Journal of medical Internet research

Results and Methodological Implications of the Digital Epidemiology of Prescription Drug References Among Twitter Users: Latent Dirichlet Allocation (LDA) Analyses.

Article

作者: Valdez, Danny ; Rao, Varun K ; Eddens, Katherine S ; Agley, Jon ; Parker, Maria A

BACKGROUND:

Social media is an important information source for a growing subset of the population and can likely be leveraged to provide insight into the evolving drug overdose epidemic. Twitter can provide valuable insight into trends, colloquial information available to potential users, and how networks and interactivity might influence what people are exposed to and how they engage in communication around drug use.

OBJECTIVE:

This exploratory study was designed to investigate the ways in which unsupervised machine learning analyses using natural language processing could identify coherent themes for tweets containing substance names.

METHODS:

This study involved harnessing data from Twitter, including large-scale collection of brand name (N=262,607) and street name (N=204,068) prescription drug-related tweets and use of unsupervised machine learning analyses (ie, natural language processing) of collected data with data visualization to identify pertinent tweet themes. Latent Dirichlet allocation (LDA) with coherence score calculations was performed to compare brand (eg, OxyContin) and street (eg, oxys) name tweets.

RESULTS:

We found people discussed drug use differently depending on whether a brand name or street name was used. Brand name categories often contained political talking points (eg, border, crime, and political handling of ongoing drug mitigation strategies). In contrast, categories containing street names occasionally referenced drug misuse, though multiple social uses for a term (eg, Sonata) muddled topic clarity.

CONCLUSIONS:

Content in the brand name corpus reflected discussion about the drug itself and less often reflected personal use. However, content in the street name corpus was notably more diverse and resisted simple LDA categorization. We speculate this may reflect effective use of slang terminology to clandestinely discuss drug-related activity. If so, straightforward analyses of digital drug-related communication may be more difficult than previously assumed. This work has the potential to be used for surveillance and detection of harmful drug use information. It also might be used for appropriate education and dissemination of information to persons engaged in drug use content on Twitter.

项与盐酸羟考酮相关的新闻（医药）

2024-06-28

·drugs

Supreme Court Rejects Purdue Pharma Opioid Settlement

FRIDAY, June 28, 2024 -- The U.S. Supreme Court on Thursday struck down a controversial settlement that drug maker Purdue Pharma had reached with victims of the opioid epidemic. The ruling threatens a massive bankruptcy plan that would have protected the Sackler family, which controls the company, against future lawsuits in exchange for sending billions to opioid victims and states harmed by the crisis. Why did the court reject the settlement? In the 5-4 vote, the justices said the bankruptcy court lacked the authority to extend that protection to the Sackler family. “The Sacklers seek greater relief than a bankruptcy discharge normally affords, for they hope to extinguish even claims for wrongful death and fraud, and they seek to do so without putting anything close to all their assets on the table,” Justice Neil Gorsuch wrote in the court's majority opinion. “Describe the relief the Sacklers seek how you will, nothing in the bankruptcy code contemplates [much less authorizes] it.” But Justice Brett Kavanaugh noted in a dissent that the ruling will have a “devastating” impact. “As a result, opioid victims are now deprived of the substantial monetary recovery that they long fought for and finally secured after years of litigation,” he wrote in the dissent. The case dealt with the fate of Purdue Pharma and its leaders, who produced and promoted the opioid medication OxyContin in the early days of the opioid epidemic. In the settlement, the Sackler family had agreed to pay $6 billion to families and states as part of an agreement to wind down the company. In exchange, the Sackler family would be protected against future civil liability claims. Purdue first marketed Oxycontin as a safer, less addictive painkiller, encouraging doctors to prescribe the drug for longer periods of time and for more routine injuries. But a series of lawsuits claimed the family continued to promote Oxycontin even after it learned how addictive the drug really was. In a statement released after the ruling, Purdue Pharma said, “We are reaching back out to creditors and renewing our pursuit of a resolution that delivers billions of dollars of value for opioid abatement and allows the company to emerge from bankruptcy as a company with a public-minded mission." In a separate statement, the families of the late Mortimer Sackler and the late Raymond Sackler expressed disappointment with the decision, CNN reported. “The Sackler families remain hopeful about reaching a resolution that provides substantial resources to help combat a complex public health crisis,” the statement read. “The unfortunate reality is that the alternative is costly and chaotic legal proceedings in courtrooms across the country. While we are confident that we would prevail in any future litigation given the profound misrepresentations about our families and the opioid crisis, we continue to believe that a swift negotiated agreement to provide billions of dollars for people and communities in need is the best way forward.” Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

专利侵权

2024-06-27

·FiercePharma

Billionaire Sackler family can't get legal immunity as part of Purdue bankruptcy deal, Supreme Court rules

Lawyers for Purdue and plaintiffs had spent years working toward a potential settlement. Now, the issue heads back to the bankruptcy court. Years of negotiations and legal proceedings surrounding a high-dollar opioid settlement for Purdue Pharma have reached a dead end at the U.S. Supreme Court. Thursday, the high court blocked a multi-billion-dollar bankruptcy agreement for Purdue Pharma and its founding family, the Sacklers. Under the proposed deal, which was worth up to $10 billion, Purdue Pharma's founding family was set to return up to $6 billion to the company's bankruptcy estate in exchange for immunity from civil lawsuits related to the nationwide opioid crisis. As shown in the new Supreme Court opinion (PDF), various courts have issued contrasting outlooks on the immunity arrangement. A bankruptcy court originally approved the Purdue plan, but a District Court in late 2021 vacated the decision. In making that ruling, the U.S. District Court for the Southern District of New York held "that nothing in the law authorizes bankruptcy courts to extinguish claims against third parties like the Sacklers, without the claimants’ consent," according to the new SCOTUS document. Then, an appeals court reversed the District Court's ruling and revived the bankruptcy court's order for a modified reorganization plan. With those back-and-forth decisions, the Supreme Court was eventually left to decide on the closely watched case. Last summer, the Supreme Court put the deal on hold while it reviewed the case, as well as fresh arguments from the Biden administration. “In a 5-4 ideologically scrambled opinion, the court ruled that a bankruptcy settlement that proposed a release of all claims and future litigation against the owners of Purdue Pharma, who had not filed for bankruptcy themselves, was a bridge too far under the bankruptcy code,” John Richer from law firm Hall Estil said in written commentary on Thursday. The Supreme Court decision sends the case back to bankruptcy court for future deliberations, according to a statement from Connecticut Attorney General William Tong. The Sackler family secured more than $10 billion from Purdue Pharma, according to reports, even as the company's powerful painkiller OxyContin served as a driving force of the nationwide opioid epidemic. In the 20 years leading to 2019, nearly a quarter of a million people in the U.S. died from prescription opioid overdoses, according to the Supreme Court opinion. The Sacklers have all by now left Purdue's board and have not collected money from the company in several years.

专利侵权

2024-05-27

·信狐药迅

两个优先1类：复星MEK1/2抑制剂复迈替尼两适应症、加科思KRAS 抑制剂格来雷塞提交上市申请|新受理（5.20-5.26）

本周药品注册受理数据，分门别类呈现，一目了然。(5.20-5.26）小编收到有些用户反应，不想收到咱们每周文章的推送提醒，而有些用户又特别需要这个提醒，在小编强烈要求下，我们给力的程序员终于实现了可以关闭提醒的功能，这个绝对全网独一家喔，不想收到提醒的，只要在信狐药迅对话框内回复关键词“拒收文章提醒”，那么就可以不受推送的打扰啦!新药上市申请药品名称企业注册分类受理号复迈替尼片上海复星医药产业发展有限公司1CXHS2400047复迈替尼片上海复星医药产业发展有限公司1CXHS2400046枸橼酸格来雷塞片北京加科思新药研发有限公司1CXHS2400044水合氯醛口服液成都亚中生物制药有限责任公司2.2CXHS2400045替妥尤单抗注射液信达生物制药(苏州)有限公司2.1CXSS2400050新药临床申请药品名称企业注册分类受理号YZG-331片中国医学科学院药物研究所1CXHL2400519ENN0403胶囊轶诺(浙江)药业有限公司1CXHL2400524DG01片苏州德亘生物医药有限公司1CXHL2400523DG01片苏州德亘生物医药有限公司1CXHL2400522BG-68501片百济神州(苏州)生物科技有限公司1CXHL2400521BG-68501片百济神州(苏州)生物科技有限公司1CXHL2400520HLX208片上海复宏汉霖生物技术股份有限公司1CXHL2400518注射用WE011上海宝龙药业股份有限公司1CXHL2400517SAL0120片深圳信立泰药业股份有限公司1CXHL2400513SAL0120片深圳信立泰药业股份有限公司1CXHL2400512XJN010鼻喷雾剂广州新济药业科技有限公司2.2CXHL2400526HKG-319国药瑞福莱药业有限公司2.2CXHL2400515HKG-319国药瑞福莱药业有限公司2.2CXHL2400514SMF-215江西施美药业股份有限公司2.3CXHL2400516青蒿琥酯片桂林南药股份有限公司2.4CXHL2400527米诺地尔泡沫剂(女用)山西振东安欣生物制药有限公司3CYHL2400101米诺地尔泡沫剂(男用)山西振东安欣生物制药有限公司3CYHL2400100甘露醇山梨醇注射液内蒙古白医制药股份有限公司3CYHL2400099HR19024注射液上海恒瑞医药有限公司2.2;2.4CXHL2400525重组破伤风疫苗(大肠埃希菌)远大赛威信生命科学(南京)有限公司1.2CXSL2400340LY01620南京吉迈生物技术有限公司1CXSL2400349注射用ZGGS18苏州泽璟生物制药股份有限公司1CXSL2400348注射用ZG005苏州泽璟生物制药股份有限公司1CXSL2400347RC148注射液荣昌生物制药(烟台)股份有限公司1CXSL2400346注射用RC118荣昌生物制药(烟台)股份有限公司1CXSL2400345JH013注射液百泰生物药业有限公司1CXSL2400342SHR-3821注射液苏州盛迪亚生物医药有限公司1CXSL2400341注射用HS-20124常州恒邦药业有限公司1CXSL2400344GenSci098注射液长春金赛药业有限责任公司1CXSL2400343SHR-7787注射液上海恒瑞医药有限公司1CXSL2400336Obexelimab注射液上海泽纳仕生物科技有限公司1CXSL2400339DCTY1102注射液北京鼎成肽源生物技术有限公司1CXSL2400338SHR-7787注射液上海恒瑞医药有限公司1CXSL2400337IBI354信达生物制药(苏州)有限公司1CXSL2400335SHR-1819注射液广东恒瑞医药有限公司1CXSL2400334mp105深圳瀛晟生物医药有限公司1CXSL2400332SYS6020注射液石药集团中奇制药技术(石家庄)有限公司1CXSL2400333仿制药申请药品名称企业注册分类受理号盐酸甲氧氯普胺注射液北京民康百草医药科技有限公司3CYHS2401573乙酰半胱氨酸注射液湖北津药药业股份有限公司3CYHS2401572盐酸倍他司汀片上海理想制药有限公司3CYHS2401560吸入用盐酸丙卡特罗溶液成都天之翼尚品医药科技有限公司3CYHS2401557复方氨基酸(15AA-II)/葡萄糖(10%)电解质注射液山东齐都药业有限公司3CYHS2401556盐酸布比卡因注射液广州艾格生物科技有限公司3CYHS2401555复方氨基酸(15AA-II)/葡萄糖(10%)电解质注射液山东齐都药业有限公司3CYHS2401554盐酸布比卡因注射液广州艾格生物科技有限公司3CYHS2401553盐酸布比卡因注射液北京民康百草医药科技有限公司3CYHS2401571盐酸布比卡因注射液北京民康百草医药科技有限公司3CYHS2401570尼麦角林片海南通用三洋药业有限公司3CYHS2401569尼麦角林片海南通用三洋药业有限公司3CYHS2401567盐酸溴己新注射液黑龙江澳利达奈德制药有限公司3CYHS2401551氨溴特罗口服溶液山东新华制药股份有限公司3CYHS2401549吲哚布芬片河北龙海药业有限公司3CYHS2401547二硫化硒洗剂安徽省先锋制药有限公司3CYHS2401529二羟丙茶碱注射液广州合和医药有限公司3CYHS2401528洛索洛芬钠细粒剂浙江百代医药科技有限公司3CYHS2401527盐酸丙美卡因滴眼液浙江莎普爱思药业股份有限公司3CYHS2401525平衡盐冲洗液西安京西双鹤药业有限公司3CYHS2401523平衡盐冲洗液西安京西双鹤药业有限公司3CYHS2401522盐酸纳美芬注射液山东如至生物医药科技有限公司3CYHS2401539法莫替丁注射液北京格林意锐医药科技有限责任公司3CYHS2401538法莫替丁注射液北京格林意锐医药科技有限责任公司3CYHS2401537氨溴特罗口服溶液广东南国药业有限公司3CYHS2401536西咪替丁注射液南京斯泰尔医药科技有限公司3CYHS2401535盐酸异丙肾上腺素注射液湖南华纳大药厂股份有限公司3CYHS2401534盐酸异丙肾上腺素注射液湖南华纳大药厂股份有限公司3CYHS2401533倍他米松磷酸钠注射液成都瑞尔医药科技有限公司3CYHS2401520左乙拉西坦缓释片佛山德芮可制药有限公司3CYHS2401519左乙拉西坦缓释片佛山德芮可制药有限公司3CYHS2401517腺苷钴胺胶囊海南全星制药有限公司3CYHS2401521吗啉硝唑氯化钠注射液辽宁民康制药有限公司4CYHS2401574甲巯咪唑片江苏德源药业股份有限公司4CYHS2401563注射用盐酸吉西他滨江苏诚康药业有限公司4CYHS2401562复方甘草酸苷片北京远方通达医药技术有限公司4CYHS2401561枸橼酸莫沙必利片上海理想制药有限公司4CYHS2401559阿莫西林克拉维酸钾片浙江巨泰药业有限公司4CYHS2401558达格列净二甲双胍缓释片(I)河南立诺制药有限公司4CYHS2401568达格列净二甲双胍缓释片(IV)河南立诺制药有限公司4CYHS2401566注射用头孢唑肟钠武汉恒泰医药科技有限公司4CYHS2401565注射用头孢唑肟钠武汉恒泰医药科技有限公司4CYHS2401564左炔诺孕酮片武汉九珑人福药业有限责任公司4CYHS2401548拉莫三嗪分散片仁合益康集团有限公司4CYHS2401546头孢托仑匹酯颗粒北京诚济制药股份有限公司4CYHS2401545巴瑞替尼片江苏万邦生化医药集团有限责任公司4CYHS2401544巴瑞替尼片江苏万邦生化医药集团有限责任公司4CYHS2401543左氧氟沙星滴眼液海南斯达制药有限公司4CYHS2401542瑞舒伐他汀依折麦布片(Ⅱ)浙江诺得药业有限公司4CYHS2401541瑞舒伐他汀依折麦布片(I)浙江诺得药业有限公司4CYHS2401540氧山东宏运达赭山气体有限公司4CYHS2401552硫酸氨基葡萄糖胶囊浙江亚克药业有限公司4CYHS2401550盐酸羟考酮缓释片江苏恩华药业股份有限公司4CYHS2401532盐酸尼卡地平注射液浙江赛默制药有限公司4CYHS2401531艾考糊精腹膜透析液芜湖道润药业有限责任公司4CYHS2401530阿司匹林肠溶片江苏济茗医药有限公司4CYHS2401526替米沙坦氨氯地平片天津恒翊药业有限公司4CYHS2401524普拉洛芬滴眼液浙江视方极医药科技有限公司4CYHS2401518帕拉米韦氯化钠注射液仁合益康集团有限公司4CYHS2401516帕拉米韦氯化钠注射液仁合益康集团有限公司4CYHS2401515硫酸镁钠钾口服用浓溶液江苏广承药业有限公司4CYHS2401514非布司他片湖北亨迪药业股份有限公司4CYHS2401513非布司他片湖北亨迪药业股份有限公司4CYHS2401512硫酸氨基葡萄糖胶囊北京百美特生物制药有限公司4CYHS2401511达可替尼片山东朗诺制药有限公司4CYHS2401510达可替尼片山东朗诺制药有限公司4CYHS2401509复方托吡卡胺滴眼液苏州欧康维视生物科技有限公司4CYHS2401508进口申请药品名称企业注册分类受理号环磷酰胺片Baxter Oncology GmbH5.1JXHS2400036艾沙妥昔单抗注射液Sanofi Winthrop Industrie2.2JXSS2400044艾沙妥昔单抗注射液Sanofi Winthrop Industrie2.2JXSS2400043VSA001注射液Arrowhead Pharmaceuticals, Inc.1JXHL2400116Astegolimab注射液F. Hoffmann-La Roche Ltd1JXSL2400103Englumafusp alfa注射液F.Hoffmann-La Roche Ltd.1JXSL2400098ABBV-382注射液AbbVie Inc.1JXSL2400097Epcoritamab注射用浓溶液AbbVie Inc.2.2JXSL2400102Epcoritamab注射用浓溶液AbbVie Inc.2.2JXSL2400101Epcoritamab注射液AbbVie Inc.2.2JXSL2400100Epcoritamab注射液AbbVie Inc.2.2JXSL2400099中药相关申请药品名称企业注册分类受理号CRA杏林中医药科技(广州)有限公司1.2CXZL2400031CRA片杏林中医药科技(广州)有限公司1.2CXZL2400030不包含原料药、医用氧、注射用水、氯化钠或葡萄糖注射液等申请，不包含再注册、一次性进口、技术转移、复审申请。

申请上市疫苗临床申请优先审批

100 项与盐酸羟考酮相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00847	盐酸羟考酮	N02AA05	-

研发状态

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
癌症疼痛	日本	Shionogi Pharma Co., Ltd.	2012-05-01
急性疼痛	中国	Bard Pharmaceuticals Ltd.	2004-01-21
慢性疼痛	中国	Bard Pharmaceuticals Ltd.	2004-01-21
疼痛	美国	Roxane Laboratories, Inc.	1998-10-26

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


CSCO2020	N/A	癌症疼痛	108	盐酸羟考酮缓释片	夢繭蓋繭衊繭鹽壓積顧(積艱艱顧淵築選顧範製) = 繭糧簾鹹壓繭鏇簾鏇艱獵衊鏇網範夢醖齋蓋範 (顧築願願夢鹹夢築鹹獵 )	积极	2020-09-19
				盐酸羟考酮缓释片+针刺治疗	襯顧艱遞淵餘膚範築鏇(淵糧積獵壓壓鬱觸網醖) = 壓膚壓壓獵鹹蓋積襯鬱簾淵壓選齋壓膚遞築壓 (膚壓願觸範鏇夢鹹壓膚 ) 更多
CSCO2020	N/A	癌症疼痛	51	体外高频热疗联合奥施康定	壓網膚構廠壓淵鹹築鹹(廠獵壓鑰範遞簾醖壓觸) = 鹽觸憲蓋壓鬱壓鹹廠襯醖範糧製窪簾繭夢構積 (範製艱選鏇淵積觸繭夢 )	积极	2020-09-19
				奥施康定	壓網膚構廠壓淵鹹築鹹(廠獵壓鑰範遞簾醖壓觸) = 糧製憲艱繭憲繭蓋壓鑰醖範糧製窪簾繭夢構積 (範製艱選鏇淵積觸繭夢 )
NCT01643772 (CTgov)	临床1期	疼痛	61	Oxycodone Hydrochloride (Oxycodone Hydrochloride Single Dose 5 mg)	網襯廠壓壓鑰衊醖鹹衊(鑰選糧鏇鬱鏇夢簾構廠) = 願糧壓壓襯積觸範鹹網選網窪顧遞築醖選構淵 (願遞壓範願餘夢築願夢, 齋餘鏇廠憲艱憲衊鹹積 ~ 願膚網齋簾衊鑰鏇鏇艱) 更多	-	2019-10-21
				Oxycodone Hydrochloride (Oxycodone Hydrochloride Single Dose 10 mg)	網襯廠壓壓鑰衊醖鹹衊(鑰選糧鏇鬱鏇夢簾構廠) = 構蓋壓製範顧鹽遞廠蓋選網窪顧遞築醖選構淵 (願遞壓範願餘夢築願夢, 糧膚鹹製淵鏇顧窪鏇夢 ~ 餘窪築觸壓蓋願構艱衊) 更多
NCT02660229 (CTgov)	临床4期	癌症疼痛	66	Oxycodone Hydrochloride (Oxycodone Hydrochloride)	選獵蓋獵艱襯膚夢鏇積(獵選齋遞鏇繭選糧艱窪) = 鑰餘憲簾選鏇餘築膚鏇顧艱憲獵廠繭選觸鏇糧 (製製糧顧範觸築齋鬱蓋, 憲遞觸艱齋願積艱壓憲 ~ 醖鏇選顧簾遞膚範獵糧) 更多	-	2018-11-19
				Morphine Sulphate (Morphine Sulphate)	選獵蓋獵艱襯膚夢鏇積(獵選齋遞鏇繭選糧艱窪) = 淵廠鬱廠獵糧網構糧壓顧艱憲獵廠繭選觸鏇糧 (製製糧顧範觸築齋鬱蓋, 壓蓋廠憲簾艱顧壓蓋廠 ~ 廠範鏇積鏇繭壓選製艱) 更多
NCT00654069 (CTgov)	临床3期	疼痛	405	Placebo (Placebo)	齋蓋窪廠願鹽觸蓋鑰製(製淵觸憲築鏇窪夢範齋) = 餘餘齋膚醖糧鏇夢鹹壓憲觸鬱繭鏇觸憲淵膚壓 (顧淵網夢觸壓壓廠鑰蓋, 夢鏇窪鏇遞襯鬱鬱糧夢 ~ 襯鹹醖鹹艱艱齋鹹壓簾) 更多	-	2018-08-22
				Acurox 7.5/30 (Acurox 7.5/30)	齋蓋窪廠願鹽觸蓋鑰製(製淵觸憲築鏇窪夢範齋) = 選獵觸鹽築獵齋觸顧築憲觸鬱繭鏇觸憲淵膚壓 (顧淵網夢觸壓壓廠鑰蓋, 鏇窪鹽蓋醖鹽蓋鬱鏇齋 ~ 鹹範齋鹽衊鏇襯憲遞顧) 更多
NCT01115101 (CTgov)	临床4期	疼痛	239	Oral Oxycodon	網範鹽糧遞構築糧選憲(願糧積鑰鹽製膚夢壓廠) = 積願憲鹽網構構製鏇鏇壓網願鹹範觸鬱廠鹹繭 (鑰遞選壓夢鹹顧網膚鹹, 鹹範蓋壓願網蓋鏇築醖 ~ 鑰獵壓築糧憲壓餘鹽膚) 更多	-	2013-02-15
NCT00726830 (CTgov)	N/A	疼痛 \| 骨髓增生异常/骨髓增生性疾病 \| 多发性骨髓瘤 ... 更多	1	methadone hydrochloride (Arm I: Opioid Rotation to Oral Methadone)	鹹築餘鏇積艱醖範願觸(廠夢選艱艱壓鹽淵鏇鏇) = 壓鏇鹽範構選蓋遞膚壓簾窪艱餘艱顧餘鹽艱選 (壓選鹹選艱繭艱觸鑰願, 製簾鹽鏇築獵範衊遞膚 ~ 鹽網醖淵鏇夢襯夢夢膚) 更多	-	2012-12-06
				oxycodone hydrochloride+morphine sulfate (Arm II: Opioid Rotation to Another Long-acting Strong Opioid)	鹹築餘鏇積艱醖範願觸(廠夢選艱艱壓鹽淵鏇鏇) = 願鬱願鏇蓋醖觸顧鏇壓簾窪艱餘艱顧餘鹽艱選 (壓選鹹選艱繭艱觸鑰願, 網憲鏇憲構積獵遞鏇觸 ~ 廠餘齋簾艱製製願顧鹹) 更多
IAS2004	N/A	降低风险行为	100	Illicit OxyContin users	鏇築艱鹽餘鹹鑰醖選襯(範蓋築觸醖願願繭觸範) = 夢網艱艱鬱艱衊選夢齋繭窪範糧夢廠鹽衊鬱衊 (選鬱艱衊憲蓋窪鹹艱鑰 ) 更多	-	2004-01-01
				Non-users	鏇築艱鹽餘鹹鑰醖選襯(範蓋築觸醖願願繭觸範) = 窪觸鏇餘夢積廠鬱構襯繭窪範糧夢廠鹽衊鬱衊 (選鬱艱衊憲蓋窪鹹艱鑰 ) 更多